Central nervous system melanoma – Basic Information

Go back

Central nervous system melanoma represents one of the most serious complications when melanoma—a dangerous form of skin cancer—spreads to the brain or spinal cord. This condition poses significant challenges for patients and medical teams alike, as it can appear either as metastatic disease from skin melanoma or, very rarely, as a primary tumor arising directly within the brain or surrounding tissues.

Understanding Central Nervous System Melanoma

Central nervous system melanoma refers to melanoma that affects the brain and spinal cord. This can happen in two main ways. Most commonly, it occurs when melanoma that started on the skin spreads to the central nervous system. This is called metastatic melanoma, meaning the cancer has traveled from its original location to another part of the body. Much more rarely, melanoma can develop directly in the central nervous system itself, arising from specialized cells called melanocytes that naturally exist in the membranes surrounding the brain and spinal cord.

Melanoma originates from melanocytes, which are pigment-producing cells that come from structures called neural crest cells during early development. These cells migrate to various parts of the body including the skin, eyes, mucous membranes, and the leptomeninges—the delicate membranes that cover the brain and spinal cord. When these cells become cancerous in the leptomeninges, they can form primary central nervous system melanoma.

Primary central nervous system melanoma is exceptionally uncommon, representing only about one percent of all melanoma cases and approximately 0.07 percent of all brain tumors. The tumor typically appears as a darkly pigmented, solid mass and often contains areas of bleeding or dead tissue. Under the microscope, it shows sheets of abnormal cells with prominent structures inside the nucleus, frequent cell division, and invasion into brain tissue.

How Common Is This Condition

Melanoma as a whole is becoming more common worldwide and currently ranks as the fifth leading cause of cancer in both men and women in the United States. The incidence of melanoma continues to rise by approximately three to seven percent each year, making it one of the twenty most common human cancers. While the number of new cases is increasing, death rates from melanoma are beginning to decrease, likely because of improved screening and early detection programs.

Melanoma is rare in children and adolescents, with the risk increasing steadily as people age. The disease is significantly more common in people with white skin compared to those with black or Asian skin. When looking at which cancers most commonly spread to the brain, melanoma ranks third, exceeded only by lung and breast cancer. However, among all solid tumors, melanoma cells have the highest tendency to settle in the brain.

Brain metastases represent a common and serious complication, especially in people with advanced-stage melanoma. Melanoma accounts for almost ten percent of all brain metastases cases. Studies show that in about 50 to 60 percent of patients with advanced melanoma, the disease will eventually spread to the central nervous system. Central nervous system metastases are found in about seven percent of melanoma patients at the time of initial diagnosis, but autopsy reports reveal that approximately 75 percent of melanoma patients die with brain metastases present.

In patients with Stage III melanoma—where the cancer has spread to nearby lymph nodes but not to distant organs—the incidence of brain metastases is about 15 percent. These brain metastases most commonly occur within the first three years after surgery. The majority of brain metastases are located in the upper part of the brain, called the supratentorial region, with about 15 percent found in the lower part, called the infratentorial region.

What Causes Melanoma and Its Spread to the Central Nervous System

Multiple factors have been identified as causes of melanoma. The most significant is exposure to ultraviolet radiation from sunlight, which damages the DNA in skin cells and can lead to cancerous changes over time. Indoor tanning, which exposes skin to concentrated ultraviolet light, also increases risk. A special treatment for certain skin conditions called PUVA therapy, which combines a light-sensitizing medication with ultraviolet A light exposure, has also been associated with increased melanoma risk.

People with light skin pigmentation and poor tanning ability face higher risk because they have less protective melanin in their skin. Certain genetic conditions increase vulnerability as well, including FAMM syndrome (familial atypical multiple mole melanoma syndrome) and atypical mole syndrome, where people develop numerous unusual-looking moles that can transform into melanoma. Having a personal history of melanoma or a family history of the disease significantly raises the likelihood of developing melanoma.

Immunosuppression—when the body’s immune system is weakened—creates additional risk. This includes people living with HIV, those with lymphoma, and individuals who have received organ transplants and must take medications to prevent rejection. Certain drugs, including TNF inhibitors (used to treat autoimmune diseases) and BRAF inhibitors (ironically, sometimes used to treat melanoma itself), have been linked to increased melanoma risk.

Risk Factors for Central Nervous System Spread

While anyone with melanoma can potentially develop central nervous system metastases, certain factors substantially increase this risk. Being male and over the age of 60 years are both associated with higher likelihood of brain involvement. Characteristics of the original melanoma tumor also matter greatly—deep, invasive lesions that penetrate far into the skin layers carry higher risk, as do tumors with ulceration, where the surface skin breaks down over the cancer.

The type of melanoma makes a difference too. Acral melanoma (which occurs on palms, soles, or under nails), lentiginous melanoma, and nodular melanoma (a raised, bump-like form) are associated with increased risk of central nervous system spread. The extent of lymph node involvement matters significantly—when more than three lymph nodes contain cancer cells, the risk of brain metastases rises considerably.

Having melanoma that has already spread to other organs at the time of diagnosis increases the likelihood of eventual brain involvement. Specific genetic mutations within the melanoma cells also play a role. Tumors with BRAF mutations or NRAS mutations—changes in genes that control cell growth—are more likely to spread to the central nervous system. Activation of a cellular signaling pathway called PI3K/AKT, which promotes cell survival and growth, also increases risk. Finally, elevated levels of an enzyme called LDH (lactate dehydrogenase) in the blood suggest more aggressive disease and higher risk of brain metastases.

⚠️ Important
The risk of developing central nervous system metastases increases with the stage of melanoma. About 37 percent of patients with Stage IV melanoma will develop central nervous system involvement. In the most recent cancer staging system, the presence of central nervous system metastases is now distinguished as a separate category called M1d, reflecting the serious nature of this complication. The detection of lesions in the central nervous system is associated with poor prognosis, and according to historical data, median overall survival after diagnosis of brain metastases was five to seven months.

Symptoms and How They Affect Patients

Central nervous system melanoma can cause a wide variety of symptoms, and its clinical presentation varies greatly from person to person. Healthcare providers should consider the possibility of brain involvement in any melanoma patient who develops neurological symptoms or behavioral changes. Interestingly, many patients initially show no symptoms at all, and brain metastases are discovered only during routine imaging scans performed as part of cancer monitoring.

When symptoms do occur, they usually result from the growing metastases themselves and from inflammatory swelling, called edema, in the brain tissue surrounding the lesions. Headache is one of the most common symptoms, often progressive and worsening over time. The headache occurs because the growing tumor and surrounding swelling increase pressure inside the skull, which the rigid bones of the skull cannot accommodate.

When primary central nervous system melanoma or leptomeningeal metastases—cancer spread to the membranes covering the brain and spinal cord—occur, patients may experience specific symptoms. A case report described a 37-year-old woman who presented with horizontal double vision and progressive headache over two weeks. Neurological examination revealed problems with eye movement, specifically difficulty moving one eye outward. Other patients may experience seizures, which occur when abnormal electrical activity in the brain is triggered by the tumor’s presence.

Focal neurological symptoms depend on which part of the brain is affected by the metastases. These can include weakness on one side of the body, numbness, difficulty speaking or understanding language, vision problems, coordination difficulties, or trouble with balance and walking. Behavioral abnormalities and personality changes may occur when tumors affect areas of the brain controlling emotion and behavior. For spinal cord involvement, patients may experience back pain, muscle weakness, numbness, paralysis of the legs, or loss of bowel and bladder control.

Prevention Strategies

Since central nervous system melanoma most commonly occurs when skin melanoma spreads to the brain, preventing melanoma in the first place represents the most effective prevention strategy. Sun protection forms the cornerstone of melanoma prevention. This includes avoiding direct sun exposure during peak intensity hours, typically between 10 a.m. and 4 p.m., when ultraviolet radiation is strongest. When outdoors, seeking shade under trees, umbrellas, or other structures reduces exposure significantly.

Wearing protective clothing makes a substantial difference in reducing ultraviolet radiation reaching the skin. Long-sleeved shirts, long pants, and wide-brimmed hats that shade the face, ears, and neck provide physical barriers. Fabrics with tight weaves offer better protection than loosely woven materials, and some clothing is specially designed with ultraviolet protection built in. Sunglasses that block both ultraviolet A and ultraviolet B rays protect the delicate skin around the eyes and may reduce risk of melanoma developing in this area.

Regular and proper use of sunscreen is essential. Broad-spectrum sunscreens that protect against both ultraviolet A and B rays with a sun protection factor of at least 30 should be applied generously to all exposed skin 15 to 30 minutes before going outdoors. Reapplication every two hours, or more frequently if swimming or sweating heavily, maintains protection. Even on cloudy days, ultraviolet radiation can penetrate clouds and cause skin damage, so sun protection remains important regardless of weather.

Avoiding indoor tanning is crucial, as tanning beds and sun lamps expose skin to concentrated ultraviolet radiation that significantly increases melanoma risk. For people with existing melanoma, regular screening and monitoring by healthcare providers allows early detection of any new melanomas or spread of existing disease. Advanced imaging techniques, including routine magnetic resonance imaging or computed tomography scans of the brain, are increasingly used to detect brain metastases at the asymptomatic stage, when they may be easier to treat. The first three years after initial melanoma surgery are particularly important for monitoring, as this is when brain metastases most commonly develop.

How Central Nervous System Melanoma Affects the Body

Understanding the changes that occur in the body when melanoma spreads to or develops in the central nervous system helps explain why symptoms occur and why this condition is so serious. The brain and spinal cord are delicate structures with limited ability to accommodate additional masses or swelling. Unlike other parts of the body where tissues can expand, the brain is contained within the rigid skull, which cannot stretch or grow. This creates a fixed amount of space, and any tumor or swelling that develops must compete for that space with normal brain tissue.

When melanoma cells establish metastases in the brain, they form masses that physically displace and compress surrounding brain tissue. As these metastases grow, they trigger an inflammatory response in the surrounding brain tissue, leading to accumulation of fluid called vasogenic edema. This swelling further increases the pressure inside the skull, a condition called increased intracranial pressure. The brain tissue becomes compressed against the skull bones, and if severe enough, parts of the brain can be pushed downward through openings in the skull base, a life-threatening situation called herniation.

The location of brain metastases determines which neurological functions are disrupted. The brain is organized into specialized regions, each controlling different functions. Metastases in the frontal lobes may affect personality, decision-making, and movement control. Those in the temporal lobes can impact memory and language comprehension. Occipital lobe involvement affects vision, while parietal lobe metastases may interfere with sensation and spatial awareness. Lesions in the cerebellum, located at the back lower part of the brain, disrupt coordination and balance.

Leptomeningeal involvement—when melanoma cells spread into the cerebrospinal fluid and the membranes surrounding the brain and spinal cord—creates particularly widespread problems. The cerebrospinal fluid flows throughout the entire central nervous system, so cancer cells floating in this fluid can settle anywhere along the brain and spinal cord surfaces. This can cause multiple simultaneous problems including headache, confusion, cranial nerve dysfunction affecting eye movement or facial sensation, and spinal nerve problems causing weakness or numbness in the limbs.

The presence of melanoma in the central nervous system also disrupts the blood-brain barrier, a specialized system of tightly connected cells lining brain blood vessels that normally prevents most substances in the blood from entering brain tissue. Melanoma metastases make this barrier leaky, allowing fluid to escape from blood vessels into brain tissue, contributing to edema. Tumors can also stimulate formation of new, abnormal blood vessels that are fragile and prone to bleeding. Hemorrhage within brain metastases is relatively common with melanoma compared to other cancers, and bleeding can cause sudden neurological deterioration.

⚠️ Important
Primary central nervous system melanoma, though rare, is particularly aggressive and easily spreads to the leptomeninges. Leptomeningeal metastasis represents one of the most serious complications for patients with this type of cancer. The prognosis is extremely poor when central nervous system melanoma has metastasized within the nervous system itself. Central nervous system metastases lead to death in 20 to 50 percent of patients, and symptomatic lesions are the immediate cause of death in about 90 percent of affected patients. In about three percent of cases, the primary tumor cannot be found even after thorough examination.

Ongoing Clinical Trials on Central nervous system melanoma

  • Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

    Not recruiting

    3 1 1
    Belgium Bulgaria Czechia Finland Germany Greece +5
  • Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

    Not recruiting

    2 1 1 1
    Germany Italy Poland Slovakia Spain

References

https://www.ncbi.nlm.nih.gov/books/NBK562305/

https://www.orpha.net/en/disease/detail/252050

https://pmc.ncbi.nlm.nih.gov/articles/PMC5398760/

https://wjso.biomedcentral.com/articles/10.1186/1477-7819-12-265

https://mdsearchlight.com/cancer/malignant-melanoma-metastatic-to-the-central-nervous-system/

https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/96483

https://www.curemelanoma.org/blog/combating-melanoma-brain-metastases-and-leptomeningeal-disease

FAQ

What is the difference between primary and metastatic central nervous system melanoma?

Primary central nervous system melanoma is extremely rare and originates directly from melanocytes in the membranes covering the brain and spinal cord, with no melanoma found elsewhere in the body. Metastatic central nervous system melanoma is much more common and occurs when melanoma that started on the skin spreads to the brain or spinal cord. About 50 to 60 percent of patients with advanced melanoma will eventually develop metastatic spread to the central nervous system.

How quickly can melanoma spread to the brain after initial diagnosis?

Brain metastases in melanoma patients most commonly occur within the first three years after surgery for the original melanoma. Studies show that about 15 percent of patients with Stage III melanoma develop brain metastases, predominantly during this three-year period. However, the timeline varies greatly between individuals depending on factors like tumor characteristics, genetic mutations, and overall disease aggressiveness.

Can you have brain metastases without symptoms?

Yes, many patients with brain metastases initially show no symptoms at all. Central nervous system metastases are increasingly being discovered at the asymptomatic stage through routine imaging scans performed as part of cancer monitoring or before starting certain treatments. Symptoms only develop as the metastases grow larger and cause increased pressure or swelling in the brain, or when they affect critical areas controlling important functions.

Why is melanoma more likely to spread to the brain than other cancers?

Melanoma cells have the highest propensity among all solid tumors for settling in the brain. This is related to their origin from neural crest cells, which gives them biological characteristics that may help them survive in the brain environment. Additionally, melanoma tends to be more aggressive and can develop genetic mutations like BRAF and NRAS that promote spread to distant organs including the central nervous system.

🎯 Key takeaways

  • Melanoma is the third most common cancer to spread to the brain, but melanoma cells have the highest tendency among all solid tumors to settle there.
  • About 50 to 60 percent of patients with advanced melanoma will develop central nervous system involvement, with 75 percent showing brain metastases at autopsy.
  • Primary central nervous system melanoma is exceptionally rare, representing only one percent of melanoma cases and 0.07 percent of all brain tumors.
  • Being male, over age 60, having deep or ulcerated melanomas, involvement of more than three lymph nodes, and certain genetic mutations significantly increase the risk of brain metastases.
  • Many brain metastases are discovered without symptoms during routine monitoring scans, emphasizing the importance of regular follow-up after melanoma diagnosis.
  • The majority of brain metastases occur within the first three years after initial melanoma surgery, making this period critical for surveillance.
  • Sun protection through shade, protective clothing, and proper sunscreen use remains the most effective prevention strategy against melanoma development.
  • Central nervous system metastases are now classified as a separate stage (M1d) in melanoma staging, reflecting the serious nature of this complication.